Deciphera’s Qinlock Hits GIST Roadblock With Phase III Failure

 
• By Alaric DeArment

The drug remains likely to get approval in Europe, but for now stuck in fourth-line treatment. The company’s pipeline lacks other near-term catalysts.

Cancer cells on scientific background.3d illustration
Deciphera reported that the Phase III trial of Qinlock in second-line GIST did not reach its primary endpoint • Source: Shutterstock

More from Anticancer

More from Therapy Areas